Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2018 08:00 ET | Source: MannKind

Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions

Oral presentation (348-OR) at 5:00 pm today Afrezza provides greater improvement in post-prandial glucose control than insulin aspart WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) --...
June 23, 2018 10:00 ET | Source: MannKind

MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions

Poster 1017-P: Afrezza provides improved Time-in-Range on Continuous Glucose Monitoring compared to insulin aspart Poster 102-LB: Hypoglycemia is reduced with use of Afrezza compared to insulin...
June 20, 2018 16:01 ET | Source: MannKind

MannKind to Host Institutional Investor and Analyst Meeting

Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes...
June 07, 2018 09:00 ET | Source: MannKind

MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase

Study achieved primary endpoint of safety and tolerabilityProgressive dosing of Treprostinil Technosphere (TreT) significantly exceeded the corresponding peak plasma and exposure levels of the maximum...
June 05, 2018 16:30 ET | Source: MannKind

MannKind Establishes Market Price Stock Purchase Plan

WESTLAKE VILLAGE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a...
May 09, 2018 16:01 ET | Source: MannKind

MannKind Corporation Reports 2018 First Quarter Financial Results

Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model)Q1 2018 Net Cash Used in Operating Activities was $21.7 millionSTAT study results...
May 09, 2018 09:00 ET | Source: MannKind

MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India

WESTLAKE VILLAGE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients...
May 02, 2018 09:00 ET | Source: MannKind

MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018

WESTLAKE VILLAGE, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management...
April 25, 2018 16:30 ET | Source: MannKind

FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary

WESTLAKE VILLAGE, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with...
April 09, 2018 16:10 ET | Source: MannKind

MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering

WESTLAKE VILLAGE, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the completion of its previously announced registered direct offering of 14,000,000...